|By Marketwired .||
|June 16, 2014 09:01 AM EDT||
NEWARK, CA--(Marketwired - June 16, 2014) - CymaBay Therapeutics, Inc. (OTCQB: CYMA), a clinical-stage biopharmaceutical company developing novel therapies to treat metabolic and rare diseases with high unmet need, today announced that its common stock has been approved for listing on the NASDAQ Capital Market and is expected to begin trading on Wednesday, June 18, 2014 under the symbol "CBAY". The company's common stock will continue to trade on the Over the Counter Bulletin Board, under the symbol "CYMA", until the market close on Tuesday, June 17, 2014.
"Uplisting to NASDAQ is an important milestone for CymaBay. We believe that trading on NASDAQ will enhance our visibility, increase our liquidity and provide access to a broader investor base," said Harold Van Wart, President and CEO of CymaBay.
CymaBay Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies to treat metabolic and rare diseases with high unmet need. Arhalofenate, the Company's lead product candidate, possesses two therapeutic actions in a single drug. In gout patients, arhalofenate is intended to prevent painful attacks in joints through an anti-inflammatory effect while at the same time promoting excretion of uric acid by the kidney, thereby addressing both the key debilitating symptom and the underlying cause of the disease. CymaBay is currently investigating arhalofenate in a 12-week Phase 2b clinical trial in patients with gout. The Company's second product candidate, MBX-8025, demonstrated favorable effects on cholesterol, triglycerides and markers of liver health in a Phase 2 clinical trial in patients with mixed dyslipidemia. MBX-8025 is currently being considered for further development in certain orphan diseases.
For additional information about CymaBay visit www.cymabay.com.
Between 2005 and 2020, data volumes will grow by a factor of 300 – enough data to stack CDs from the earth to the moon 162 times. This has come to be known as the ‘big data’ phenomenon. Unfortunately, traditional approaches to handling, storing and analyzing data aren’t adequate at this scale: they’re too costly, slow and physically cumbersome to keep up. Fortunately, in response a new breed of technology has emerged that is cheaper, faster and more scalable. Yet, in meeting these new needs they...
Dec. 3, 2016 12:15 AM EST Reads: 1,742
Dec. 2, 2016 11:15 PM EST Reads: 866
Dec. 2, 2016 11:15 PM EST Reads: 1,671
Dec. 2, 2016 10:30 PM EST Reads: 1,720
Dec. 2, 2016 08:30 PM EST Reads: 350
Dec. 2, 2016 08:30 PM EST Reads: 4,968
Dec. 2, 2016 08:15 PM EST Reads: 1,554
Dec. 2, 2016 07:00 PM EST Reads: 3,912
Dec. 2, 2016 06:45 PM EST Reads: 3,981
Dec. 2, 2016 06:30 PM EST Reads: 1,475
Dec. 2, 2016 05:15 PM EST Reads: 366
Dec. 2, 2016 05:00 PM EST Reads: 4,076
Dec. 2, 2016 04:45 PM EST Reads: 2,103
Dec. 2, 2016 04:45 PM EST Reads: 1,970
Dec. 2, 2016 04:15 PM EST Reads: 366